BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 28870908)

  • 1. Bcl-2-like Protein 11 (BIM) Expression Is Associated with Favorable Prognosis for Patients with Cervical Cancer.
    Kim BW; Cho H; Ylaya K; Kitano H; Chung JY; Hewitt SM; Kim JH
    Anticancer Res; 2017 Sep; 37(9):4873-4879. PubMed ID: 28870908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of fibroblast growth factor receptor family members is associated with prognosis in early stage cervical cancer patients.
    Choi CH; Chung JY; Kim JH; Kim BG; Hewitt SM
    J Transl Med; 2016 May; 14(1):124. PubMed ID: 27154171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bim may be a poor prognostic biomarker in breast cancer patients especially in those with luminal A tumors.
    Maimaiti Y; Dong L; Aili A; Maimaitiaili M; Huang T; Abudureyimu K
    Cancer Biomark; 2017 Jul; 19(4):411-418. PubMed ID: 28582840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The possible role of p53 and bcl-2 expression in cervical carcinomas and their premalignant lesions.
    Dimitrakakis C; Kymionis G; Diakomanolis E; Papaspyrou I; Rodolakis A; Arzimanoglou I; Leandros E; Michalas S
    Gynecol Oncol; 2000 Apr; 77(1):129-36. PubMed ID: 10739702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of Bax, Bcl-2, and p53 expressions in cervical squamous cell carcinoma treated by radiotherapy.
    Wootipoom V; Lekhyananda N; Phungrassami T; Boonyaphiphat P; Thongsuksai P
    Gynecol Oncol; 2004 Sep; 94(3):636-42. PubMed ID: 15350352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53R2 overexpression in cervical cancer promotes AKT signaling and EMT, and is correlated with tumor progression, metastasis and poor prognosis.
    Jiang C; Xu R; Li XX; Wang YY; Liang WQ; Zeng JD; Zhang SS; Xu XY; Yang Y; Zhang MY; Wang HY; Zheng XFS
    Cell Cycle; 2017 Sep; 16(18):1673-1682. PubMed ID: 28841361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nuclear Expression of GS28 Protein: A Novel Biomarker that Predicts Worse Prognosis in Cervical Cancers.
    Cho U; Kim HM; Park HS; Kwon OJ; Lee A; Jeong SW
    PLoS One; 2016; 11(9):e0162623. PubMed ID: 27611086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive significance of combined LAPTM4B and VEGF expression in patients with cervical cancer.
    Meng F; Tan S; Liu T; Song H; Lou G
    Tumour Biol; 2016 Apr; 37(4):4849-55. PubMed ID: 26526574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression levels of survivin, Bcl-2, and KAI1 proteins in cervical cancer and their correlation with metastasis.
    Zhou XL; Wang M
    Genet Mol Res; 2015 Dec; 14(4):17059-67. PubMed ID: 26681053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of eukaryotic initiation factor 5A2 (EIF5A2) is associated with cancer progression and poor prognosis in patients with early-stage cervical cancer.
    Yang SS; Gao Y; Wang DY; Xia BR; Liu YD; Qin Y; Ning XM; Li GY; Hao LX; Xiao M; Zhang YY
    Histopathology; 2016 Aug; 69(2):276-87. PubMed ID: 26799253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High Expression of CCDC34 Is Associated with Poor Survival in Cervical Cancer Patients.
    Liu LB; Huang J; Zhong JP; Ye GL; Xue L; Zhou MH; Huang G; Li SJ
    Med Sci Monit; 2018 Nov; 24():8383-8390. PubMed ID: 30458457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bim is an independent prognostic marker in intrahepatic cholangiocarcinoma.
    Zhang H; Jenkins SM; Lee CT; Harrington SM; Liu Z; Dong H; Zhang L
    Hum Pathol; 2018 Aug; 78():97-105. PubMed ID: 29698699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nuclear Y-box-binding protein-1 is a poor prognostic marker and related to epidermal growth factor receptor in uterine cervical cancer.
    Nishio S; Ushijima K; Yamaguchi T; Sasajima Y; Tsuda H; Kasamatsu T; Kage M; Ono M; Kuwano M; Kamura T
    Gynecol Oncol; 2014 Mar; 132(3):703-8. PubMed ID: 24486603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of the bcl-2 apoptotic family of proteins in primary and recurrent cervical cancer.
    Crawford RA; Caldwell C; Iles RK; Lowe D; Shepherd JH; Chard T
    Br J Cancer; 1998 Jul; 78(2):210-4. PubMed ID: 9683295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Relationship between PUMA and BIM expression in colorectal cancer and tumor invasion, metastasis and prognosis].
    Yuan H; Tu SL; He XJ
    Zhonghua Wai Ke Za Zhi; 2013 Jun; 51(6):547-51. PubMed ID: 24091272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemoradiotherapy response prediction model by proteomic expressional profiling in patients with locally advanced cervical cancer.
    Choi CH; Chung JY; Kang JH; Paik ES; Lee YY; Park W; Byeon SJ; Chung EJ; Kim BG; Hewitt SM; Bae DS
    Gynecol Oncol; 2020 May; 157(2):437-443. PubMed ID: 32107047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of Bcl-2 family proteins and association with clinicopathological characteristics of oral squamous cell carcinoma.
    Coutinho-Camillo CM; Lourenço SV; Nishimoto IN; Kowalski LP; Soares FA
    Histopathology; 2010 Aug; 57(2):304-16. PubMed ID: 20716171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BH3-only protein Bim predicts advanced stage of cutaneous melanoma.
    Gambichler T; Rooms I; Scholl L; Stockfleth E; Stücker M; Sand M
    J Eur Acad Dermatol Venereol; 2016 Nov; 30(11):1926-1929. PubMed ID: 27356803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BCL2-like 11 intron 2 deletion polymorphism is not associated with non-small cell lung cancer risk and prognosis.
    Cho EN; Kim EY; Jung JY; Kim A; Oh IJ; Kim YC; Chang YS
    Lung Cancer; 2015 Oct; 90(1):106-10. PubMed ID: 26271547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer.
    Soh SX; Siddiqui FJ; Allen JC; Kim GW; Lee JC; Yatabe Y; Soda M; Mano H; Soo RA; Chin TM; Ebi H; Yano S; Matsuo K; Niu X; Lu S; Isobe K; Lee JH; Yang JC; Zhao M; Zhou C; Lee JK; Lee SH; Lee JY; Ahn MJ; Tan TJ; Tan DS; Tan EH; Ong ST; Lim WT
    Oncotarget; 2017 Jun; 8(25):41474-41486. PubMed ID: 28467813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.